Melevodopa/carbidopa

Drug Profile

Melevodopa/carbidopa

Alternative Names: Carbidopa/melevodopa; CHF 1512; CNP 1512; GT 1512; Levodopa methyl ester/carbidopa; Sirio; V 1512

Latest Information Update: 25 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi
  • Developer Chiesi; Vernalis
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Neuroprotectants
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 25 Aug 2015 No recent reports on development identified - Phase-II for Parkinson's disease in USA and Europe (PO)
  • 10 Sep 2008 The US FDA has agreed on a special protocol assessment (SPA) for the phase III programme of V 1512 for Parkinson's disease
  • 19 Sep 2007 Vernalis is in discussions with the US FDA to agree on a special protocol assessment for the phase III programme of V 1512 for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top